C. Crivera

发表

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care

J. Schein, O. Baser, P. Wells, 2019, Journal of health economics and outcomes research.

Bayesian data analysis in observational comparative effectiveness research: rationale and examples.

W. Olson, S. Lynch, J. Panish, 2013, Journal of comparative effectiveness research.

Duration of anticoagulant therapy and VTE recurrence in patients with cancer

A. Khorana, W. Nelson, J. Schein, 2019, Supportive Care in Cancer.

Current practice patterns and patient persistence with anticoagulant treatments for cancer‐associated thrombosis

A. Khorana, W. Nelson, J. Schein, 2017, Research and practice in thrombosis and haemostasis.

Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?

A. Khorana, W. Nelson, J. Schein, 2016, Thrombosis research.

Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials

Manesh R Patel, C. White, W. Peacock, 2016, Current medical research and opinion.

Outcomes associated with endovascular treatment among patients with acute ischemic stroke in the USA

A. Rai, R. Kumari, C. Crivera, 2019, Journal of NeuroInterventional Surgery.

Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users

W. Olson, J. Schein, S. Lynch, 2015, Journal of medical economics.

Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population

E. Muser, R. Dirani, Jiyoon C. Choi, 2010, Journal of medical economics.

Evaluation of machine learning methodology for the prediction of healthcare resource utilization and healthcare costs in patients with critical limb ischemia—is preventive and personalized approach on the horizon?

Shun-Chiao Chang, J. Schein, J. Berger, 2020, EPMA Journal.

The value of sPESI for risk stratification in patients with pulmonary embolism

J. Schein, O. Baser, P. Wells, 2019, Journal of Thrombosis and Thrombolysis.

External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality

J. Schein, W. Peacock, C. Coleman, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches

J. Schein, W. Peacock, C. Coleman, 2016, Thrombosis Journal.

Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination.

J. Schein, W. Peacock, C. Coleman, 2016, Thrombosis research.

Health‐care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN‐CHOICE Trial Population

M. Prins, Yongling Xiao, P. Prandoni, 2018, Chest.

Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.

J. Schein, O. Baser, P. Wells, 2017, Clinical therapeutics.

Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies

J. Schein, P. Wells, C. Baugh, 2017, Current medical research and opinion.

Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US

S. Jagannath, A. Fu, N. Shah, 2021, Oncology and Therapy.

Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions

K. Gersing, L. Alphs, R. Dirani, 2010, Journal of medical economics.

Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population

M. Prins, Yongling Xiao, P. Prandoni, 2018 .

Abstract 15539: Anticoagulant Treatment Patterns for Cancer-Associated Thrombosis in a Commercial Insurance Population

A. Khorana, J. Schein, K. McCrae, 2017 .

Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure

C. McHorney, W. Nelson, J. Schein, 2015, Current medical research and opinion.

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results

Yongling Xiao, J. Schein, P. Wells, 2018, Journal of medical economics.

Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis

J. Schein, P. Wells, W. Peacock, 2017, BMC Pulmonary Medicine.

Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low‐Risk Patients with Pulmonary Embolism

J. Schein, W. Peacock, C. Coleman, 2016, Pharmacotherapy.

Effect Of Prasugrel Vs Clopidogrel On Hospital Readmission Among Acute Coronary Syndrome Patients Treated With Prasugrel

W. Olson, J. Schein, S. Lynch, 2014 .

COMPARISON OF RIVAROXABAN OR WARFARIN USE FOR VENOUS THROMBOEMBOLISM ON INPATIENT LENGTH OF STAY

J. Kline, W. Olson, J. Schein, 2016 .

Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer

A. Khorana, K. McCrae, D. Milentijevic, 2016, Journal of medical economics.

Abstract 13611: Adherence to Non-VKA Oral Anticoagulant Medications Based on the Pharmacy Quality Alliance Measure

C. McHorney, W. Nelson, J. Schein, 2015 .

Abstract 366: Pharmacy Quality Alliance Measure: Adherence to Non-Warfarin Oral Anticoagulant Medication

W. Nelson, J. Schein, P. Lefebvre, 2015 .

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

R. Dirani, C. Kozma, C. Crivera, 2011, BMC psychiatry.

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

R. Dirani, C. Kozma, C. Crivera, 2011, BMC psychiatry.

External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications

J. Schein, W. Peacock, C. Coleman, 2016, BMC Health Services Research.

Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed

W. Nelson, J. Schein, E. Witt, 2016, Patient preference and adherence.

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.

W. Olson, W. Nelson, J. Schein, 2015, Clinical therapeutics.

Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications

W. Nelson, J. Schein, P. Lefebvre, 2015, Current medical research and opinion.

Clinical and economic outcomes among hospitalized patients with acute coronary syndrome: an analysis of a national representative Medicare population

J. Schein, L. Boulanger, Shih-Yin Chen, 2013, ClinicoEconomics and outcomes research : CEOR.

Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysis.

C. McHorney, J. Schein, D. Sobieraj, 2016, International journal of cardiology.

Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations

S. Jagannath, M. Sussman, N. Shah, 2021, Clinical Drug Investigation.

Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review

M. Sussman, C. Crivera, J. Benner, 2021, Advances in Therapy.

Impact of Inhaled Corticosteroid-Induced Oropharyngeal Adverse Effects on Treatment Patterns and Costs in Asthmatic Patients: Results from a Delphi Panel

A. Amin, M. Kaliner, T. Bramley, 2005 .

Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

S. Jagannath, A. Krishnan, M. Vogel, 2021 .

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

S. Jagannath, A. Krishnan, M. Mehra, 2021, EJHaem.

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism

Yongling Xiao, J. Schein, J. Berger, 2017, Research and practice in thrombosis and haemostasis.

Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

A. Khorana, J. Schein, J. Berger, 2017, Clinical Therapeutics.

Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.

D. Porter, R. Richards, A. Deol, 2022, Future oncology.

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation

A. Khorana, J. Schein, K. McCrae, 2018, American journal of hematology.

The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine

S. Silberstein, R. Cady, J. Hulihan, 2007, Headache.

Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients

C. McHorney, E. Peterson, J. Schein, 2018, Current medical research and opinion.

Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users

C. McHorney, P. Lefebvre, F. Laliberté, 2018, PloS one.

Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.

C. McHorney, E. Peterson, W. Nelson, 2016, Clinical therapeutics.

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer

A. Khorana, W. Nelson, J. Schein, 2018, American journal of hematology.

Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin

J. Schein, I. Abbass, Yihua Xu, 2019, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics.

J. Menzin, J. Meyers, R. Dirani, 2010, Psychiatric services.

Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism

J. Schein, O. Baser, P. Wells, 2019, Journal of health economics and outcomes research.

Benefit of early discharge among patients with low-risk pulmonary embolism

Craig I Coleman, W Frank Peacock, Li Wang, 2017, PloS one.

VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism

A. Khorana, J. Schein, K. McCrae, 2017 .

An answer to “anticoagulant treatment of cancer‐associated venous thromboembolism: Interpreting real‐world data with caution”

A. Khorana, W. Nelson, J. Schein, 2018, American journal of hematology.

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma

S. Jagannath, A. Cohen, S. Valluri, 2023, Oncology and Therapy.

Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.

W. Olson, J. Schein, P. Lefebvre, 2016, Clinical therapeutics.

Interrupted Time Series Analysis in Clinical Research

L. Matowe, J. Korth-Bradley, C. Crivera, 2003, The Annals of pharmacotherapy.

Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events

E. Nutescu, B. Bookhart, C. Crivera, 2015, International journal of clinical practice.

Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis

A. Khorana, W. Nelson, J. Schein, 2015 .

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims

J. Stephenson, J. Panish, R. Dirani, 2012, International journal of clinical practice.

Indirect Costs Associated With Nonadherence to Treatment for Bipolar Disorder

W. Bunn, R. Dirani, K. Yu-Isenberg, 2010, Journal of occupational and environmental medicine.

Evaluation of health services use following the initiation of risperidone long‐acting therapy among schizophrenia patients in the veterans health administration

L. Kazis, R. Dirani, C. Crivera, 2011, Journal of clinical pharmacy and therapeutics.

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

C. McHorney, E. Peterson, J. Schein, 2017, Journal of managed care & specialty pharmacy.

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions

David M. Smith, J. Kline, J. Schein, 2016, Journal of the American Heart Association.

Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?

J. Schein, P. Wells, W. Peacock, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin

J. Schein, P. Wells, C. Baugh, 2017, Internal and Emergency Medicine.

Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin.

David M. Smith, J. Kline, J. Schein, 2016, Clinical therapeutics.

Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism

J. Schein, P. Wells, W. Peacock, 2016, Journal of Thrombosis and Thrombolysis.

The Economic Burden of Acute Coronary Syndromes for Employees and Their Dependents: Medical and Productivity Costs

K. Nair, R. Page, V. Ghushchyan, 2013, Journal of occupational and environmental medicine.

External validation of the In‐hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) multivariable prediction rule

C. Coleman, G. Fermann, W. F. Peacock, 2016, International journal of clinical practice.

Validation of the multivariable In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule within an all-payer inpatient administrative claims database

J. Schein, W. Peacock, C. Coleman, 2015, BMJ Open.